Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823410 | 1.00 | CTSS (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12356974 | 0.95 | CTSS (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL3179611 | 0.95 | CTSS (0.55) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL15216111 | 0.92 | ADRB3 (0.56) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL10283477 | 0.91 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12369322 | 0.91 | CTSS (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL15216112 | 0.87 | ADRB3 (0.59) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL15216115 | 0.86 | ADRB3 (0.50) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13090456 | 0.86 | CTSS (0.58) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL12369352 | 0.86 | CTSS (0.61) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| US-8765966-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2013-10-10 | — | — | US | disclosed |
| US-8481748-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8410313-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309737-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CTSS 1777/4885ADRB3 4690/4885ADRA2B 4708/4885 |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 43/4885ADRB3 4433/4885ADRA2B 4379/4885 |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CTSS 1777/4885ADRB3 4690/4885ADRA2B 4708/4885 |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CTSS 1777/4885ADRB3 4690/4885ADRA2B 4708/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 43/4885ADRB3 4433/4885ADRA2B 4379/4885 |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, PHOSPHO1 | CTSS 1889/4885ADRB3 4667/4885ADRA2B 4701/4885 |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CTSS 1777/4885ADRB3 4690/4885ADRA2B 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.